MRSA (methicillin-resistant Staphylococcus aureus) is a type of bacteria that is resistant to several widely used antibiotics. This means infections with MRSA can be harder to treat than other bacterial infections. In this application note, a high throughput flow reactor is used to efficiently scale up, on a 100g scale, synthesis of a key intermediate for Zyvox™ (Upjohn)—the first example of a new class of oxazolidinone antibiotics that are active against MRSA.

Access this application note, courtesy of Uniqsis.